Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments
The event will showcase data from several of the Company's most advanced clinical programs, such as PRGN-3005 UltraCAR-T®, PRGN-3006 UltraCAR-T®, PRGN-2009 OTS AdenoVerse™ Immunotherapy and PRGN-2012 OTS AdenoVerse™ Immunotherapy.
Helen Sabzevari, PhD, President and CEO of Precigen Mary L. (Nora) Disis, MD, University of Washington (UW) Professorof Medicine, Director of UW Center for Translational Medicine, Professor in the Clinical Research Division at Fred Hutch and a lead investigator for the PRGN-3005 clinical study David Sallman, MD, Assistant Member in the Department of Malignant Hematologyat the H. Lee Moffitt Cancer Center & Research Instituteand a lead investigator for the PRGN-3006 clinical study James L. Gulley, MD, PhD, Branch Chief and Director of the Medical Oncology Service at the National Institutes of Health(NIH) and a lead investigator for the PRGN-2009 clinical study Clint T. Allen, MD, Principal Investigator with the Section on Translational Tumor Immunology at the NIHand a lead investigator for the PRGN-2012 clinical study
Participants may register and access the live webcast through
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the
For more information, contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-host-rd-update-virtual-event-on-november-4th-to-share-clinical-developments-301410331.html